RYR2 and catecholaminergic polymorphic ventricular tachycardia: In all previously mentioned research CPVT-iPSC-CMs were generated from patients carrying mutations in RYR2 providing insights in pathophysiologic mechanisms and potential new drug treatment for this type of CPVT.